NEW YORK (GenomeWeb) – Interpace Diagnostics reported after the close of the market on Wednesday that its fourth quarter revenues rose 22 percent.

For the three-month period ended Dec. 31, Interpace's revenues were $3.1 million, compared $2.6 million the prior year.

"2016 was a breakout year as we delivered strong revenue growth, significant cost reductions and right sizing as we completed our transition to a fully-integrated, commercially based molecular diagnostics company," Interpace President and CEO Jack Stover said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A federal grand jury has indicted Elizabeth Holmes and Ramesh Balwani for alleged wire fraud in conjunction with their activities at Theranos.

Nature News reports that some developers are nervous about GitHub's acquisition by Microsoft.

A direct-to-consumer genetic testing company sent out used spit kits, CNBC reports.

In PLOS this week: comparison of commercial bisulfite kits, new method to predict essential proteins, and more